SCHEMBL1979897

SCHEMBL1979897

Cc1cccc(C)c1Oc1ccc(NC(C)(C)C(N)=O)cn1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.39
HTR2C P28335 1/20 0.38
RAB9A P51151 3/20 0.38
MAPK1 P28482 3/20 0.37
PKM P14618 1/20 0.37
GALR3 O60755 1/20 0.37
MAPT P10636 5/20 0.36
NPSR1 Q6W5P4 1/20 0.36
HTT P42858 1/20 0.36
LTA4H P09960 1/20 0.35
OXTR P30559 1/20 0.35
TSHR P16473 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
NOTUM Q6P988 1/20 0.35
NPC1 O15118 1/20 0.35
GAA P10253 2/20 0.35
ALDH1A1 P00352 1/20 0.35
GFER P55789 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1979896 0.80 MAPT (0.43) KEAP1HTR2CRAB9AMAPK1PKM
SCHEMBL1982717 0.78 OXTR (0.41) HTR2CRAB9AMAPK1PKMGALR3
SCHEMBL1979061 0.78 SCN9A (0.41) KEAP1HTR2CRAB9ALTA4HALDH1A1
SCHEMBL13832518 0.76 NOTUM (0.49) HTR2CRAB9APKMMAPTNPSR1
SCHEMBL1979058 0.75 KMT2A (0.46) HTR2CRAB9ALTA4HNOTUMALDH1A1
SCHEMBL12593958 0.75 HTR2C (0.41) HTR2CRAB9AMAPK1PKMGALR3
SCHEMBL1980327 0.74 HTR2C (0.42) HTR2CRAB9AMAPK1PKMGALR3
SCHEMBL15303440 0.74 RAB9A (0.33) KEAP1HTR2CRAB9AMAPK1PKM
SCHEMBL13721575 0.72 PKM (0.40) HTR2CRAB9AMAPK1PKMGALR3
SCHEMBL21980939 0.71 KMT2A (0.42) HTR2CRAB9AMAPK1PKMGALR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200163964-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2020-05-28 US disclosed
US-10632118-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2020-04-28 US disclosed
US-20180338974-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2018-11-29 US disclosed
US-10058551-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2018-08-28 US disclosed
US-20180021336-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2018-01-25 US disclosed
US-9849131-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2017-12-26 US disclosed
US-20170065585-A1 IMIDAZOLIDINEDIONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2017-03-09 US disclosed
EP-2509961-B1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LTD (GB) 2016-03-09 EP disclosed
US-20160058737-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2016-03-03 US disclosed
US-9216967-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2015-12-22 US disclosed
US-8722695-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2014-05-13 US disclosed
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2012-11-15 US disclosed
EP-2509961-A1 IMIDAZOLIDINEDIONE DERIVATIVES Autifony Therapeutics Limited (GB) 2012-10-17 EP disclosed
WO-2011069951-A1 IMIDAZOLIDINEDIONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2011-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180338974-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 KEAP1 3193/4885HTR2C 334/4885RAB9A 1989/4885
US-20180021336-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 KEAP1 3193/4885HTR2C 334/4885RAB9A 1989/4885
US-10632118-B2 Imidazolidinedione derivatives KCND3, KCNK3, KCNA3 KEAP1 3193/4885HTR2C 334/4885RAB9A 1989/4885
US-20170065585-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 KEAP1 3193/4885HTR2C 334/4885RAB9A 1989/4885
US-20160058737-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 KEAP1 3193/4885HTR2C 334/4885RAB9A 1989/4885
US-10058551-B2 Imidazolidinedione derivatives KCND3, KCNK3, KCNA3 KEAP1 3193/4885HTR2C 334/4885RAB9A 1989/4885
US-20200163964-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 KEAP1 3193/4885HTR2C 334/4885RAB9A 1989/4885
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 KEAP1 2956/4885HTR2C 223/4885RAB9A 1466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.